TARGETED THERAPY IN THE PALLIATIVE TREATMENT OF PLATINUM-RESISTANT RECURRENT OVARIAN CANCER COMPLICATED BY ASCITES
Keywords:
Abstract
Ascites in ovarian cancer can reach any volume. As a rule, a small effusion without clinical manifestations is not removed, it regresses against the background of systemic chemotherapy. In ovarian cancer ascites is rarely very large, but the abdomen can be huge due to the combination of several litres of fluid with a large mass of tumour. Ascites that interferes with normal life is necessarily evacuated. Due to the accumulation of fluid can cause shortness of breath and swelling of the legs, impaired breathing and nutrition - vomiting just eaten and drunk. In such situations, a laparocentesis must be performed.
Similar Articles
-
Main Role Of Morphogenetic Between Fgf-23 And Sklotho In The Development Of Herdic And Vasicular Models In Chronic Key Disease Patients
The American Journal of Medical Sciences and Pharmaceutical Research: No. 04 (2021) / Nodira Mirshavkatovna Alikhanova, Aikhojaeva Mokhira Akmalovna, Nazarova Nozimakhon Sunnatilla Kizi, Charos Bakhtiyorovna Musakhanova, -
The Role Of rs1799883 Polymorphism Of The FABP2 Gene In The Pathogenesis Of Nosological Syntropy Of Gallstone Disease And Metabolic Syndrome
The American Journal of Medical Sciences and Pharmaceutical Research: No. 06 (2021) / Raximov Anvar Pulatboevich, Ismailov O’ktam Safaevich, Batirov Davronbek Yusupovich, -
UNUSUAL MANIFESTATIONS OF COELIAC DISEASE: A CASE STUDY APPROACH
The American Journal of Medical Sciences and Pharmaceutical Research: No. 07 (2023) / Dr. Mamta Chaudhary, -
Predictors Of The Development Of Chronic Kidney Disease In Patients With Chronic Obstructive Pulmonary Disease
The American Journal of Medical Sciences and Pharmaceutical Research: No. 04 (2021) / Kayumova Gulnoz Karimovna , Akhmedova Nilufar Sharipovna , Umurova Nigora Mavlyanovna , -
Optimising Hygienic And Surgical Aspects Of Prevention, Early Diagnosis And Treatment Of Echinococcal Disease
The American Journal of Medical Sciences and Pharmaceutical Research: No. 03 (2021) / Jasurbek Mahmudjonovich Butaboev , Guli Islamovna Shaikhova, Adham Lutfullaevich Kasymov , -
ANEMIA IS A CHRONIC DISEASE
The American Journal of Medical Sciences and Pharmaceutical Research: No. 09 (2022) / Auezova Svetlana Satniyazovna, -
Coronary Heart Disease
The American Journal of Medical Sciences and Pharmaceutical Research: No. 02 (2021) / Ishankulova Nasiba Nurmamadovna , -
Features Of The Use Of Antioxidant Drugs In The Treatment Of Psoriatic Disease
The American Journal of Medical Sciences and Pharmaceutical Research: No. 02 (2021) / Akhmedov Shavkat Kurbonalievich , Oripov Rustam Anvarovich , Ashirov Zohijon Fayozjonovich , Nuralieva Rano Matyakubovna , Haydarov Musomiddin Mukhammadievich, -
Careful Attention To The History Of Chronic Urticaria Is One Of The Important Factors Of Productive Therapy
The American Journal of Medical Sciences and Pharmaceutical Research: No. 02 (2021) / Akhmedov Shavkat Kurbonalievich , Ashirov Zohijon Fayozjonovich , Oripov Rustam Anvarovich , Siddikov Olim Abdullaevich, Haydarov Musomiddin Mukhammadievich, -
The Role Of Polymorphic Genes Of Matrix Metalloproteinases (MMPS) And Their Tissue Inhibitors In The Development Of Renal Dysfunction In Chronic Glomerulonephritis In Children
The American Journal of Medical Sciences and Pharmaceutical Research: No. 06 (2021) / Bazarova N.S., Ziyadullaev Sh.Kh.,
References
Рахимов Н. М. и др. МЕХАНИЗМ РАЗВИТИЯ ПЕРИТОНЕАЛЬНОГО ЗЛОКАЧЕСТВЕННОГО АСЦИТА ПРИ РЕЦИДИВЕ РАКА ЯИЧНИКА //Клиническая и экспериментальная онкология. – 2020. – №. 4. – С. 45-49.
Anderson R. D. American Society of Hospital Pharmacists. ASHP statement on the use of medications for unlabeled uses //Am J Hosp Pharm. – 1992. – Т. 49. – №. 8. – С. 2-006
Bertozzi S. et al. Nanotechnologies in obstetrics and cancer during pregnancy: a narrative review //Journal of Personalized Medicine. – 2022. – Т. 12. – №. 8. – С. 1324
Cazzaniga M. E. et al. Metronomic chemotherapy //Cancers. – 2021. – Т. 13. – №. 9. – С. 2236.
Colombo N. et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease //Annals of Oncology. – 2019. – Т. 30. – №. 5. – С. 672-705.
Dzhurayev M. D. et al. Key Priorities For Immunohistochemical Testing In Predicting Cervical Cancer Recurrence //The American Journal of Medical Sciences and Pharmaceutical Research. – 2021. – Т. 3. – №. 06. – С. 87-93.
duBois A. et al. A Phase III //Randomized, Double-Blind Trial of Pazopanib Versus Placebo in Women Who Have Not Progressed After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (AEOC): Results of an International Intergroup Trial (AGO-OVAR 16) American Society of Clinical Oncology. – 2013. – Т. 31.
Fountzilas E., Said R., Tsimberidou A. M. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits //Expert opinion on investigational drugs. – 2018. – Т. 27. – №. 2. – С. 155-162.
Green A. E., Rose P. G. Pegylated liposomal doxorubicin in ovarian cancer //International journal of nanomedicine. – 2006. – Т. 1. – №. 3. – С. 229.
Lee A. T. J., Jones R. L., Huang P. H. Pazopanib in advanced soft tissue sarcomas //Signal transduction and targeted therapy. – 2019. – Т. 4. – №. 1. – С. 16.
Oaknin A. et al. A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study. – 2012.
Gulia S. et al. Pazopanib and oral cyclophosphamide in women with platinum-resistant or-refractory epithelial ovarian cancer //JCO Global Oncology. – 2020. – Т. 6. – С. 542-547
Gupta S. et al. A phase II study of oral metronomic combination therapy in relapsed epithelial ovarian cancer. – 2013. Pandey A. et al. Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience //South Asian Journal of Cancer. – 2016. – Т. 5. – №. 02. – С. 059-062.
Perrone M. G. et al. Translational Theragnosis of Ovarian Cancer: where do we stand? //Current Medicinal Chemistry. – 2020. – Т. 27. – №. 34. – С. 5675-5715
Saiyed M. M., Ong P. S., Chew L. Off‐label drug use in oncology: a systematic review of literature //Journal of clinical pharmacy and therapeutics. – 2017. – Т. 42. – №. 3. – С. 251-258
Saidkulov B. et al. Recurrent ovarian cancer: mechanisms of development of peritoneal malignant ascites //European Journal of Molecular and Clinical Medicine. – 2020. – Т. 7. – №. 2. – С. 2423-2428.
Zhang Y. et al. The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent Ovarian Cancer: A Systematic Review and Meta-Analysis //American Journal of Clinical Oncology. – 2023. – Т. 46. – №. 6. – С. 25
